Clinical Scorecard: AVONELLE-X Findings: Stable Vision, Anatomy, and Thickness in nAMD
At a Glance
| Category | Detail |
|---|---|
| Condition | Neovascular age-related macular degeneration (nAMD) |
| Key Mechanisms | Dual mechanism of action of faricimab targeting VEGF and Ang-2 |
| Target Population | Patients with wet macular degeneration previously treated in TENAYA and LUCERNE trials |
| Care Setting | Ophthalmology clinical trials and specialized retina care centers |
Key Highlights
- Faricimab treatment maintained stable best-corrected visual acuity (BCVA), retinal anatomy, and central subfield thickness over 3 to 4 years.
- More than 60% of patients achieved extended dosing intervals up to 16 weeks, with potential for intervals beyond 20 weeks.
- Switching from aflibercept to faricimab reduced persistent retinal fluid by 44% in difficult-to-treat patients.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of nAMD based on clinical and imaging criteria consistent with TENAYA and LUCERNE trial enrollment.
Management
- Use faricimab in a treat-and-extend regimen to maintain stable vision and anatomy over long-term treatment.
- Consider switching patients with persistent retinal fluid on aflibercept to faricimab for improved fluid resolution.
- Extend treatment intervals up to 16 weeks based on patient response, with potential for longer intervals in future protocols.
Monitoring & Follow-up
- Regular assessment of best-corrected visual acuity and retinal anatomy including central subfield thickness.
- Monitor for adverse events consistent with prior studies; no occlusive vasculitis reported in AVONELLE-X.
- Evaluate for macular atrophy in long-term follow-up as data becomes available.
Risks
- Faricimab demonstrated a consistent and clean safety profile with no new safety signals over 4 years.
- No cases of occlusive vasculitis reported in the extension trial.
Patient & Prescribing Data
Patients with nAMD previously treated in TENAYA and LUCERNE trials, including those switched from aflibercept.
Median of approximately 7 injections over years 3 and 4 with stable vision outcomes; 75% of patients with baseline 20/40 vision maintained this level at 4 years.
Clinical Best Practices
- Implement treat-and-extend dosing strategies with faricimab to reduce injection burden while maintaining efficacy.
- Counsel patients on the importance of timely and adequate treatment frequency to preserve driving-level vision (20/40 or better).
- Consider faricimab’s dual mechanism of action as a therapeutic advantage in managing persistent retinal fluid and long-term disease stability.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
